Analysis of RCTs showed that clopidogrel pretreatment was not associated with a reduction of death (absolute risk, 1
11; P Dec 28, 2011 · With the addition of 13 studies, the benefit associated with the gain-of-function genotype is slightly less (RR, 0
A non-randomised study of clopidogrel pretreatment As there is scant evidence for preloading with P2Y12 antiplatelet agents, patients on oral anticoagulants
Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in
Newer P2Y12 inhibitors are
1 , 2 , 3 Indeed, such high loading dose regimens provide the advantage of enhancing platelet inhibition and improving clopidogrel responsiveness
DOI: 10
MACCEs Meta-analysis results for MACCEs
Several studies have shown that the effectiveness of clopidogrel for secondary stroke prevention is reduced among CYP2C19 LOF carriers
2011 Dec 28;306(24):2704-14
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
n1332 PubMed Google Scholar CONTENT: Clopidogrel, one of the most commonly prescribed medications, is a prodrug requiring CYP450 biotransformation
The previously published meta-analysis which included 32 studies with publication date before the year 2012 (29 studies published in English and 3 studies published in Chinese), showed the concomitant use of PPI and clopidogrel to be associated with higher MACEs with OR: 1
Clopidogrel blocks the P2Y 12 ADP receptor on platelets and has been shown to reduce cardiovascular events in patients presenting with an acute coronary syndrome (ACS), particularly in those undergoing percutaneous coronary intervention (PCI)
Objective To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes
2021;78(1) To the Editor: The meta-analysis by Dr Mega and colleagues shows that among patients treated with clopidogrel for percutaneous coronary intervention, carriage of 1 reduced-function CYP2C19 allele is associated with an increased risk of major adverse cardiovascular events (hazard ratio [HR], 1
DAPT combining aspirin with either ticagrelor or clopidogrel was superior to aspirin alone, but there was no statistically significant difference found between the 2 regimens for the primary outcome
3% of the global burden of disease
Only this active metabolite targets the P2Y12 receptor on platelets, resulting in inhibition of platelet aggregation
Findings In this secondary analysis of a randomized clinical trial that included 2836 adults, clopidogrel plus aspirin was associated with a significant reduction in the risk of new stroke in patients
59–2
16-18 Postulated hypotheses for these findings included the adverse effect profile of ticagrelor and issues with compliance
JAMA
Review Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects
In the meta-analysis, we included 206 455 patients in a time frame of almost 4 decades from 1981 to 2018
In recent years, the relationship between Cyp2C19*2 gene polymorphism and clopidogrel resistance reflected by platelet function assay has been studied extensively, but there is no clear conclusion yet